Please try another search
Breaking News
For the nine months ended 30 September 2016, Arno Therapeutics Inc revenues was not reported. Net loss increased 29% to $9.7M. Higher net loss reflects Other income/(expense), net decrease from $3.2M (income) to $1.3M (expense), Interest Expense increase from $1K to $15K (expense), Interest Income decrease of 49% to $4K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$0.37 to -$0.23.
Period Ending: | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 |
---|---|---|---|---|
Total Revenue | 0 | 0 | 0 | 0 |
Gross Profit | ||||
Operating Income | -2.23 | -3.31 | -2.83 | -2.7 |
Net Income | -3.85 | -2.14 | -3.71 | -3.99 |
Period Ending: | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 |
---|---|---|---|---|
Total Assets | 2.36 | 1.1 | 2.92 | 0.36 |
Total Liabilities | 8.07 | 6.32 | 6.95 | 8.99 |
Total Equity | -5.71 | -5.22 | -4.02 | -8.62 |
Period Ending: | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 |
---|---|---|---|---|
Period Length: | 9 Months | 6 Months | 3 Months | 12 Months |
Cash From Operating Activities | -5.47 | -4.33 | -2.65 | -9.97 |
Cash From Investing Activities | 0 | |||
Cash From Financing Activities | 7.53 | 5.21 | 5.27 | 2.08 |
Net Change in Cash | 2.06 | 0.87 | 2.62 | -7.88 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review